Cargando…

A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone

BACKGROUND: This study attempted to develop a nomogram for predicting clinically significant prostate cancer (cs-PCa) in the transition zone (TZ) with the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) score based on biparametric magnetic resonance imaging (bp-MRI) and clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Chaogang, Pan, Peng, Chen, Tong, Zhang, Yueyue, Dai, Guangcheng, Tu, Jian, Jiang, Zhen, Zhao, Wenlu, Shen, Junkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261422/ https://www.ncbi.nlm.nih.gov/pubmed/34295730 http://dx.doi.org/10.21037/tau-21-49

Ejemplares similares

A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study
por: Zhang, Yueyue, et al.
Publicado: (2020)

Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy
por: Yang, Shuo, et al.
Publicado: (2020)

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
por: Chen, Tong, et al.
Publicado: (2022)

Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
por: Chen, Tong, et al.
Publicado: (2018)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
por: Li, Tianping, et al.
Publicado: (2022)

Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer
por: Rudolph, Madhuri Monique, et al.
Publicado: (2020)

Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
por: Wang, Yunhan, et al.
Publicado: (2023)

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions
por: Bonaffini, Pietro Andrea, et al.
Publicado: (2023)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone
por: Wen, Jing, et al.
Publicado: (2022)

Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study
por: Jin, Pengfei, et al.
Publicado: (2023)

PI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
por: Camacho, Andrés, et al.
Publicado: (2023)

Morphologic perfusion patterns and PI-RADSv2.1 in transition zone prostate cancer
por: Garmer, M., et al.
Publicado: (2023)

Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement
por: Hötker, Andreas M., et al.
Publicado: (2020)

Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
por: Zhang, Yu, et al.
Publicado: (2018)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Natale, Caleb, et al.
Publicado: (2021)

Impact of PI-RADS v2 on indication of prostate biopsy
por: Rozas, George de Queiroz, et al.
Publicado: (2019)

An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study
por: Hiremath, Amogh, et al.
Publicado: (2021)

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells
por: Wei, Chaogang, et al.
Publicado: (2018)

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study
por: Zhou, Yongheng, et al.
Publicado: (2023)

A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients
por: Hu, Beibei, et al.
Publicado: (2023)

A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
por: Song, Yan, et al.
Publicado: (2023)

PI-RADS v2.1: What has changed and how to report
por: Scott, Robin, et al.
Publicado: (2021)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
por: Viana, Publio Cesar Cavalcanti, et al.
Publicado: (2019)

Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone
por: Ono, Ashita, et al.
Publicado: (2023)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

PI-RADS 2.1 und strukturierte Befundung der Magnetresonanztomographie der Prostata
por: Hötker, Andreas, et al.
Publicado: (2021)

Axumin ((18)F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest
por: Becher, Ezequiel, et al.
Publicado: (2022)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
por: Li, Mou, et al.
Publicado: (2021)

Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI
por: Barth, Borna K., et al.
Publicado: (2021)

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions
por: Hu, Can, et al.
Publicado: (2022)

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men – East meets West
por: Kubihal, Vijay, et al.
Publicado: (2022)

Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI‐RADS 3–5 regions of interest
por: Stone, Nelson, et al.
Publicado: (2021)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions
por: Gravina, Michela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5imu629qvghof9n0039ed700nl